Zimmer Biomet, a leading orthopedic device company, exceeded third-quarter earnings expectations and raised its full-year revenue guidance. The company also announced the broad commercial launch of its new Z1 Femoral Hip System, a triple-taper femoral system designed for total hip arthroplasty.
JMP Securities has initiated coverage on Enovis Corporation (ENOV), a medical technology company specializing in orthopedics, with a ‘Market Outperform’ rating and a price target of $62. The analyst believes Enovis is undervalued, citing the successful integration of the LimaCorporate acquisition and the potential for significant revenue and earnings growth.
The global hip reconstruction devices market is projected to experience significant growth in the coming years, reaching US$ 6.7 billion by 2034. This expansion is fueled by the rising prevalence of hip-related conditions like osteoarthritis, an aging global population, and technological advancements in hip replacement procedures. The report delves into the market’s segmentation, key players, and regional insights.
